Results 201 to 210 of about 36,256 (261)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) [PDF]

, 2018
et al,, Picus, Joel
core   +1 more source

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. [PDF]

J Clin Oncol
Bradley JD, Sugawara S, Lee KH, Ostoros G, Demirkazik A, Zemanova M, Sriuranpong V, Gelatti ACZ, de Menezes JJ, Zurawski B, Newton M, Chander P, Jia N, Bielecka ZF, Özgüroğlu M, PACIFIC-2 Investigators.   +15 more
europepmc   +1 more source

Supplementary Figure S8 from Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC

Pablo Llerena, Hani Samarah, Kathryn Nunes, Zhao Lin, Kelly Bridgham, Sruti Tekumalla, Amiti Jain, Larry A. Harshyne, Sanket K. Shukla, Ioannis Vathiotis, Madalina Tuluc, Stacey Gargano, John R. Eisenbrey, Scott W. Keith, David M. Cognetti, Voichita Bar‐Ad, Adam Luginbuhl, Rita Axelrod, Rajanikanth Vadigepalli, Hushan Yang, Diana Whitaker‐Menezes, Megan Roche, Mỹ G. Mahoney, Athanassios Argiris, Charalambos Solomides, Jennifer M. Johnson, Mouadh Barbirou, Amanda Miller, Andrew P. South, Ramkrishna Mitra, Alban J. Linnenbach, Ubaldo Martinez‐Outschoorn, Joseph Curry   +32 more
openalex   +1 more source

Pharmacovigilance Insights Into Immune Checkpoint Inhibitor-Induced Risk of Paraneoplastic Syndrome: A Large-Scale Real World Study. [PDF]

CNS Neurosci Ther
Tang B, Song X, Sun Y, Wan J, Hu W, Ma Y, Lin Y, Zhang J, Wang Y, Feng H, Luo P, Guo D, Qu X.   +12 more
europepmc   +1 more source

Supplementary Table S1 from Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial [PDF]

Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández, Ricardo Collado, Ricardo Fernández, Sergio Vázquez, Juan Antonio Virizuela, Pablo Gajate, Albert Font, Núria Laínez, Elena Sevillano-Fernández, Osvaldo Graña‐Castro, Luis Beltrán, Rodrigo Madurga, Cristina Rodríguez‐Antona, Pedro Berraondo, Sergio Ruiz‐Llorente, Jesús García-Donás   +17 more
openalex   +1 more source

Comparison of efficacy and safety of first-line immunotherapy combined with chemotherapy in extensive-stage small cell lung cancer, a retrospective study. [PDF]

Sci Rep
Dong X, Yao X, Li R, Li Y, Li Y.
europepmc   +1 more source

1437 Analysis by treatment period and liver function in EMERALD-1: a phase 3 study of durvalumab ± bevacizumab + TACE in participants with embolization-eligible unresectable hepatocellular carcinoma [PDF]

Stephen L. Chan, Masatoshi Kudo, Thomas Decaens, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Yasuaki Arai, Mohamed Bouattour, В. В. Бредер, Shi-Ming Lin, Jeong Heo, Jean‐Marie Péron, Vincenzo Mazzaferro, Quang Nguyen, Joong‐Won Park, Lünan Yan, Alejandro Molina Alavez, Chang-Fang Chiu, Kwong‐Ming Kee, Florinda Santos, Aibing Xu, Anil Veluvolu, Yoshitaka Inaba, Satheesh Chiradoni Thungappa, Farshid Dayyani, David Hsieh, Vaidehi Dave, Claire Morgan, Kerry Parsons, Mallory Makowsky, Riccardo Lencioni, Bruno Sangro   +31 more
openalex   +1 more source

Navigating the Therapeutic Pathway and Optimal First-Line Systemic Therapy for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors. [PDF]

Medicina (Kaunas)
Shin HP, Lee M.
europepmc   +1 more source

Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer [PDF]

, 2018
Bradley, Jeffrey D, Roach, Michael C, Robinson, Cliff G   +2 more
core   +1 more source

A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab [PDF]

Ting Zou, Zhuoyang Li, Tianhong Wang, Shuang Deng, S. Wang, Yusi Hua   +5 more
openalex   +1 more source